PDCD1 and non-small cell lung carcinoma: In 2015, two PD-1 inhibitors/antibodies (nivolumab and pembrolizumab) have received US Food and Drug Administration (FDA) approval for the use in advanced NSCLC after platinum-based chemotherapy.